UKINETS2023 Poster Presentations Section (27 abstracts)
Investigation of the utility of [68Ga]Ga-DOTA-TATE PET/CT scanning in patients with Multiple Endocrine Neoplasia Type 1 (MEN1) with suspected pancreatic neuroendocrine tumours
Dr Kalyan Vamshi Vemulapalli 1,2 , Dr. Gopinath Gnanasegaran 1,2 , Dr. Gowri Ratnayake 2 , Professor Ashley Grossman 2 , Dr. Aimee Hayes 2 , Dr. Bernard Khoo 2 , Professor Martyn Caplin 2 & Dr. Shaunak Navalkissoor 1,2
1Nuclear Medicine Department, Royal Free Hospital, London, United Kingdom; 2Neuroendocrine Tumour Unit, Royal Free Hospital, London, United Kingdom
Purpose: To evaluate the added benefit and accuracy of [68Ga]Ga-DOTA-TATE PET/CT scans in detecting pancreatic neuroendocrine tumours, compared to conventional cross-sectional imaging with CT or MRI scans, in patients with multiple endocrine neoplasia type 1 (MEN1)
Methods: A retrospective analysis was performed comparing the initial [68Ga]Ga-DOTA-TATE PET/CT to the respective contemporary CT or MRI imaging in patients with MEN1 under the care of a tertiary endocrine centre. Imaging and electronic patient records were analysed to identify treatment plans and the records of multidisciplinary team discussions.
Results: In total, 85% (n=39/46) of patients with MEN1 had a [68Ga]Ga-DOTA-TATE PET/CT study in the electronic patient record; 23 of these also had contemporaneous contrast enhanced CT scans, while 18 had MRI scans. [68Ga]Ga-DOTA-TATE PET/CT detected a total of 47 pancreatic lesions compared to 25 on CT, while [68Ga]Ga-DOTA-TATE PET/CT detected 36 lesions compared to 24 on MRI. In 18% of patients (n=7/39), pancreatic lesions were detected on [68Ga]Ga-DOTA-TATE PET/CT which were not seen on MRI or CT, while 33% (n=13/39) had extra-pancreatic lesions detected on [68Ga]Ga-DOTA-TATE PET/CT that were not seen on MRI or CT. As a result of findings on [68Ga]Ga-DOTA-TATE PET/CT scanning, a change of management was indicated in 82% (n=32/39) of patients. Of these, 33% (n=13/39) were referred for further investigations, 23% (n=9/39) were started on somatostatin analogues, while 15% (n=6/39) were recommended surgery.
Conclusion: In patients with MEN1, [68Ga]Ga-DOTA-TATE PET/CT was shown to detect a greater number of pancreatic and metastatic lesions compared to conventional cross-sectional CT or MRI imaging. Management plans were changed in most patients following their initial [68Ga]Ga-DOTA-TATE PET/CT. Therefore, we suggest that such radionuclide scanning should be an integral part of the investigation of patients with MEN1.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more